SCHEMBL1246982

SCHEMBL1246982

Cc1cc(-c2ccc(NC(=O)[C@H](C)N)cc2)c2ccccc2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 2/20 0.48
IGF1R P08069 1/20 0.48
CIT O14578 1/20 0.48
GAA P10253 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
OPRL1 P41146 1/20 0.46
OPRK1 P41145 1/20 0.46
MMP9 P14780 1/20 0.45
LTA4H P09960 1/20 0.44
MEN1 O00255 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44
APH1A Q96BI3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6260764 0.81 TAAR1 (0.67) TAAR1L3MBTL1ALDH1A1CITGAA
SCHEMBL1751436 0.76 TAAR1 (1.00) TAAR1ALDH1A1CITNPC1RAB9A
SCHEMBL4652086 0.76 TAAR1 (1.00) TAAR1ALDH1A1CITNPC1RAB9A
SCHEMBL4059859 0.75 MAPT (0.49) L3MBTL1ALDH1A1NPC1RAB9AMEN1
SCHEMBL18731749 0.74 CYP1A2 (0.58) ALDH1A1
SCHEMBL1104820 0.74 CYP1A2 (0.62) ALDH1A1
SCHEMBL28129147 0.73 CYP1A2 (0.53) L3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL28317085 0.73 CYP1A2 (0.56) ALDH1A1GAANPC1RAB9AMEN1
Iodide SCHEMBL30847747 0.73 CYP1A2 (0.60) ALDH1A1
SCHEMBL4741417 0.72 TAAR1 (0.79) TAAR1ALDH1A1GAANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459734-B1 NOVEL PEPTIDASE SUBSTRATES BIOMERIEUX SA (FR) 2014-10-08 EP claimed
US-8592174-B2 Peptidase substrates bioMérieux, S.A. (FR) 2013-11-26 US claimed
EP-2459734-A2 NOVEL PEPTIDASE SUBSTRATES Biomérieux (FR) 2012-06-06 EP claimed
US-20120122135-A1 Novel Peptidase Substrates bioMerieux, SA (FR) 2012-05-17 US claimed
WO-2011012809-A2 NOVEL PEPTIDASE SUBSTRATES bioMérieux (FR) 2011-02-03 WO claimed
EP-2459734-B1 NOVEL PEPTIDASE SUBSTRATES BIOMERIEUX SA (FR) 2014-10-08 EP disclosed
US-8592174-B2 Peptidase substrates bioMérieux, S.A. (FR) 2013-11-26 US disclosed
EP-2459734-A2 NOVEL PEPTIDASE SUBSTRATES Biomérieux (FR) 2012-06-06 EP disclosed
US-20120122135-A1 Novel Peptidase Substrates bioMerieux, SA (FR) 2012-05-17 US disclosed
WO-2011012809-A2 NOVEL PEPTIDASE SUBSTRATES bioMérieux (FR) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122135-A1 Novel Peptidase Substrates CPN1, CTRL, ANPEP TAAR1 939/4885L3MBTL1 1347/4885ALDH1A1 2722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.